12,923 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Bought by Guardian Wealth Advisors LLC NC

Guardian Wealth Advisors LLC NC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,923 shares of the company’s stock, valued at approximately $153,000.

Several other large investors have also made changes to their positions in the company. Russell Investments Group Ltd. raised its position in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new position in Roivant Sciences in the fourth quarter valued at about $39,000. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. raised its position in Roivant Sciences by 27.0% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after purchasing an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN raised its position in Roivant Sciences by 84.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company’s stock valued at $89,000 after purchasing an additional 3,426 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ROIV has been the topic of several research reports. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Monday, April 21st.

Insider Transactions at Roivant Sciences

In related news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the transaction, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares of the company’s stock, valued at $9,345,374.98. This trade represents a 19.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,669,500 shares of company stock valued at $18,064,847. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ ROIV opened at $10.65 on Monday. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The firm has a market cap of $7.60 billion, a price-to-earnings ratio of -71.00 and a beta of 1.23. The stock’s 50-day simple moving average is $10.49 and its 200-day simple moving average is $11.11.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, research analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.